Promising research. Open questions.
A selected tracker of obesity treatments still in development. A successful trial is a step in the evidence process; it does not establish UK authorisation, a launch date, a price or NHS funding.
Retatrutide
Investigational GIP, GLP-1 and glucagon receptor agonist.
Latest event: 14 November 2026What the evidence says so far
Lilly’s November 2026 update describes phase 3 research across obesity-related outcomes. Its October announcement explicitly says retatrutide has not been authorised by any regulator.
What remains uncertain
A future UK licence, final prescribing instructions, routine availability and NHS funding have not been established. Trial findings do not verify products offered by online sellers.
Sources & further reading
These links support the information above; they do not imply endorsement of this website.
CagriSema
Investigational combination of the amylin analogue cagrilintide and GLP-1 receptor agonist semaglutide.
Latest event: 14 November 2026What the evidence says so far
REDEFINE 9 adds evidence about lower doses. The manufacturer’s 14 November update continues to describe CagriSema as investigational.
What remains uncertain
The study does not establish the better active dose, superiority over other obesity medicines, a UK launch date or an NHS access route.
Sources & further reading
These links support the information above; they do not imply endorsement of this website.
MariTide
Maridebart cafraglutide: an antibody–peptide conjugate that activates GLP-1 receptors and blocks GIP receptors.
Latest event: 3 November 2026What the evidence says so far
Amgen’s 3 November 2026 update lists ongoing MARITIME-1 and MARITIME-2 weight-management trials, alongside studies of cardiovascular, sleep-apnoea and other outcomes. Less frequent dosing is being studied.
What remains uncertain
The final benefit–risk profile, any approved dosing interval, UK authorisation, price and NHS eligibility remain unestablished. A trial dosing schedule is not a licensed regimen.
Sources & further reading
These links support the information above; they do not imply endorsement of this website.
Where do newly authorised tablets belong?
A treatment stops being “upcoming” in a country once it is authorised there, even if funding or launch questions remain. Our news pages explain the UK status of Wegovy tablets and Foundayo separately.
Read the UK access explainers →